Document is current
Any future updates will be listed below
-
Authors
Glans, Isabelle
Nägga, Katarina
Gustavsson, Anna-Märta
Stomrud, Erik
Nilsson, Peter M
Melander, Olle
Hansson, Oskar
Palmqvist, Sebastian
-
Funding
Funding for this research was provided by:
Lund University
- License Information
-
More Information
Article History
Received: 10 November 2023
Accepted: 12 June 2024
First Online: 26 June 2024
Declarations
:
: All participants received information about the study and gave written consent to participate. Ethical approval was given by the Ethical Committee of Lund University, Lund, Sweden <b>(</b>LU 51–90, LU 532–2006).
: Not applicable.
: SP has acquired research support (for the institution) from ki elements / ADDF. In the past two years, he has received consultancy/speaker fees from Bioartic, Biogen, Lilly, and Roche. OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past two years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. KN has received consultancy fee from Biogen in the past two years. The remaining authors have no disclosures relevant to the manuscript.
